Synlogic reports Q2 2023 net loss of $15.0M; Phase 3 PKU trial initiated

SYNLOGIC, INC.

2023-Q2 EPS reported -$0.44 revenue$209,000

Net loss $15.0M ($0.21/sh) vs $15.8M ($0.22/sh) in Q2 2022; cash $46.3M.
Revenue $35K from Roche collaboration, down from $152K year-over-year.
R&D expenses $11.8M; G&A $3.9M, both slightly lower than prior year.
Initiated pivotal Phase 3 Synpheny-3 trial for labafenogene marselecobac (SYNB1934) in PKU (n=150).
FDA granted Fast Track designation; WHO approved INN 'labafenogene marselecobac'.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SYNLOGIC, INC. reported the quarter ended June 30, 2023 results: revenue $35 thousand, net income consolidated net loss of $15.0 million, or $0.21 per share.

Period: the quarter ended June 30, 2023
Revenue: $35 thousand
Net income: consolidated net loss of $15.0 million, or $0.21 per share
Result: reported results

Exact text from the filing

2023 Financial Results and Financial Outlook As of June 30, 2023, Synlogic had cash and cash equivalents of $46.3 million. Revenue for the three months ended June 30, 2023 was $35 thousand compared to $152 thousand for the corresponding period in 2022. Revenue in both periods was primarily associated with the ongoing research collaboration with Roche for the

View on SEC.gov

Browse all earnings releases →

SYNLOGIC, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-040929

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.